Citius Pharmaceuticals
CTXR
74 hedge funds and large institutions have $30.4M invested in Citius Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 9 closing their positions.
915% more call options, than puts
Call options by funds: $721K | Put options by funds: $71K
222% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 9
80% more capital invested
Capital invested by funds: $16.9M → $30.4M (+$13.5M)
35% more funds holding
Funds holding: 55 → 74 (+19)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0.25% more ownership
Funds ownership: 0.39% → 0.64% (+0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.56M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.15M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.67M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.03M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$825K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$407K |
| 2 |
Millennium Management
New York
|
-$318K |
| 3 |
Jane Street
New York
|
-$229K |
| 4 |
WAS
Wealth Advisory Solutions
Indiianapolis,
Indiana
|
-$182K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$117K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$117K | -4,004 | Closed |
|
|
BFM
77
Boothbay Fund Management
New York
| – | -$88K | -3,008 | Closed |
|
78
Squarepoint
New York
| – | -$86K | -2,941 | Closed |
|
|
JF
79
Jump Financial
Chicago,
Illinois
| – | -$77.4K | -2,646 | Closed |
|
80
Group One Trading
Chicago,
Illinois
| – | -$64.4K | -1,956 | Closed |
|
|
LIP
81
Lighthouse Investment Partners
Palm Beach Gardens,
Florida
| – | -$42.3K | -1,445 | Closed |
|
|
YIH
82
Y-Intercept (HK)
Hong Kong
| – | -$12.4K | -424 | Closed |
|
|
SSC
83
Syverson Strege & Co
West Des Moines,
Iowa
| – | -$2.51K | -86 | Closed |
|
CTXR Hedge Fund Activity: Q2 2023 in Review
74 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2023, worth a combined $30.4M — up 80% from $16.9M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CTXR positions and 9 closed out — a net gain of 20 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $7.56M. The largest seller was Susquehanna International Group, cutting an estimated $407K.
- 74 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2023, up from 55 in Q1 2023.
- Funds reported $30.4M of Citius Pharmaceuticals stock for Q2 2023, up 80% quarter-over-quarter.
- 29 funds opened new Citius Pharmaceuticals positions in Q2 2023 and 9 closed out, a net change of +20 holders.
- The largest Citius Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $7.56M added.
- The largest Citius Pharmaceuticals seller in Q2 2023 was Susquehanna International Group, an estimated $407K sold.
Based on aggregated 13F filings for Q2 2023.